Recent reports described that a pharmacological inhibition of β-catenin could reactivate cancer immunity by increasing dendritic cells, upregulating CCL4, and promoting the intratumoral infiltration of CD8+ T cells in various tumor models, including colon cancer [49,50,51]. The gene discussed is CCL4; the disease is colonic neoplasm.